spacer
home > ict > autumn 2020 > using technology to streamline clinical data management
PUBLICATIONS
International Clinical Trials

Using Technology to Streamline Clinical Data Management

Clinical trial success depends on both operational efficiencies and highquality submission-ready data. Data management plays a key role in ensuring that both are achieved. Yet, departmental silos within companies, coupled with the common expectation that data are only the responsibility of data managers, hinder the access and use of operational data by the teams responsible for decisions around study management and trial execution. When combined with the industry’s hesitance to embrace technological innovation, along with disparate data collection and storage systems, gaining actionable insights from study data can be a challenge. Additionally, many solutions lack an option for sites to monitor their own operational performance, leading to disconnects between the sponsor and sites.

By modernising clinical trials and leveraging cloud-based applications and advanced analytics, organisations can harmonise their use of data across departments, gain greater insights into data and trial status, and provide sites with a greater level of independence.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jeff Rogers, President of Crucial Data Solutions (CDS), leads and optimises CDS’ business to meet the industry’s evolving technology requirements and drive new growth. He directly supports the ongoing development and introduction of CDS’ TrialKit platform that is being used today by sponsors and CROs to manage thousands of clinical trials around the world. With 25 years of industry experience, including leadership roles at multiple clinical technology companies, Jeff has been instrumental in developing and promoting technology solutions that help life science companies become more efficient, reduce costs, and get new drugs to market faster.

Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals appoints José Luis Bartolomé as Operational Excellence Director

[Noáin, Spain, September 30, 2020]3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, appoints a new member to the management team with the incorporation of José Luis Bartolomé as Operational Excellence and Continuous Improvement Director.
More info >>

White Papers

Accelerating the Time from DNA to Material

Merck

Cell line development is a critical step in upstream process development for monoclonal antibodies (mAbs). Unfortunately, the search for the bestproducing clone can be labor- and resource-intensive and is often compared with looking for a needle in a haystack. Cells must first be engineered to produce the biologic of interest and the cell line generated from a high producing clone must deliver a sufficiently high titer to support clinical studies, and ultimately commercialization of the therapeutic.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement